[{"address1": "650 Castro Street", "address2": "Suite 450", "city": "Mountain View", "state": "CA", "zip": "94041", "country": "United States", "phone": "650 200 0412", "website": "https://www.altoneuroscience.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; and ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD. The company was incorporated in 2019 and is headquartered in Mountain View, California.", "fullTimeEmployees": 76, "companyOfficers": [{"maxAge": 1, "name": "Dr. Amit  Etkin M.D., Ph.D.", "age": 47, "title": "Founder, Chairman of the Board, CEO & President", "yearBorn": 1977, "fiscalYear": 2024, "totalPay": 995998, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nicholas C. Smith", "age": 35, "title": "CFO & Chief Business Officer", "yearBorn": 1989, "fiscalYear": 2024, "totalPay": 680467, "exercisedValue": 0, "unexercisedValue": 217377}, {"maxAge": 1, "name": "Mr. Michael C. Hanley M.B.A.", "age": 51, "title": "Chief Operating Officer", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 623006, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Dan  Segal B.Sc. (Hons), BCom, CA, MSc", "age": 62, "title": "Co-Founder & Strategic Advisor", "yearBorn": 1962, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Erin R. McQuade J.D.", "age": 49, "title": "General Counsel, Chief Administrative Officer & Corporate Secretary", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Adam  Savitz M.D., Ph.D.", "age": 58, "title": "Chief Medical Officer", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 579569, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jessica  Powell", "age": 49, "title": "Chief Development Officer", "yearBorn": 1975, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 3.59, "open": 3.61, "dayLow": 3.7, "dayHigh": 3.92, "regularMarketPreviousClose": 3.59, "regularMarketOpen": 3.61, "regularMarketDayLow": 3.7, "regularMarketDayHigh": 3.92, "payoutRatio": 0.0, "forwardPE": -1.358885, "volume": 150732, "regularMarketVolume": 150732, "averageVolume": 226383, "averageVolume10days": 96780, "averageDailyVolume10Day": 96780, "bid": 3.75, "ask": 3.97, "bidSize": 2, "askSize": 1, "marketCap": 105598744, "fiftyTwoWeekLow": 1.6, "fiftyTwoWeekHigh": 15.04, "fiftyDayAverage": 2.8, "twoHundredDayAverage": 3.19855, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -16677147, "profitMargins": 0.0, "floatShares": 17884113, "sharesOutstanding": 27076600, "sharesShort": 2147256, "sharesShortPriorMonth": 2014513, "sharesShortPreviousMonthDate": 1751241600, "dateShortInterest": 1753920000, "sharesPercentSharesOut": 0.0793, "heldPercentInsiders": 0.0748, "heldPercentInstitutions": 0.64062, "shortRatio": 15.28, "shortPercentOfFloat": 0.1007, "impliedSharesOutstanding": 27076600, "bookValue": 4.559, "priceToBook": 0.85545075, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "netIncomeToCommon": -64859000, "trailingEps": -2.39, "forwardEps": -2.87, "enterpriseToEbitda": 0.24, "52WeekChange": -0.66466033, "SandP52WeekChange": 0.1513431, "quoteType": "EQUITY", "currentPrice": 3.9, "targetHighPrice": 15.0, "targetLowPrice": 4.0, "targetMeanPrice": 10.33333, "targetMedianPrice": 10.0, "recommendationMean": 1.375, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 6, "totalCash": 147584992, "totalCashPerShare": 5.451, "ebitda": -69609000, "totalDebt": 25309000, "quickRatio": 18.155, "currentRatio": 18.434, "debtToEquity": 20.508, "returnOnAssets": -0.24716, "returnOnEquity": -0.42785, "freeCashflow": -38465000, "operatingCashflow": -55082000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ANRO", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1755902400, "regularMarketTime": 1755892802, "exchange": "NYQ", "messageBoardId": "finmb_1675972978", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "shortName": "Alto Neuroscience, Inc.", "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 8.6351, "regularMarketPrice": 3.9, "marketState": "CLOSED", "epsTrailingTwelveMonths": -2.39, "epsForward": -2.87, "fiftyDayAverageChange": 1.1000001, "fiftyDayAverageChangePercent": 0.3928572, "twoHundredDayAverageChange": 0.7014501, "twoHundredDayAverageChangePercent": 0.21930254, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.4 - Strong Buy", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1706884200000, "postMarketChangePercent": 1.79487, "postMarketPrice": 3.97, "postMarketChange": 0.06999993, "regularMarketChange": 0.31, "regularMarketDayRange": "3.7 - 3.92", "fullExchangeName": "NYSE", "averageDailyVolume3Month": 226383, "fiftyTwoWeekLowChange": 2.3000002, "fiftyTwoWeekLowChangePercent": 1.4375001, "fiftyTwoWeekRange": "1.6 - 15.04", "fiftyTwoWeekHighChange": -11.139999, "fiftyTwoWeekHighChangePercent": -0.7406914, "fiftyTwoWeekChangePercent": -66.466034, "earningsTimestampStart": 1763150400, "earningsTimestampEnd": 1763150400, "isEarningsDateEstimate": true, "displayName": "Alto Neuroscience", "trailingPegRatio": null, "__fetch_time": "2025-08-23"}]